Further information about ImMucin and Vaxil can be found on Vaxil’s website – vaxilbio.com

About Vaxil

Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

Dr. Lior Carmon, founder and CEO said “We have succeeded in identifying a novel way to detect cancer onset and progression. This is an invaluable tool which will significantly enhance our ability to provide effective relief to these patients who are eligible to be treated with ImMucin and is yet another validation of our VaxHit technology”.

 

About Vaxil

Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

For further details see the attached PDF file

About Vaxil

Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

The article entitled "ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors" describes ImMucin's unique ability to bind multiple MHC Class I and Class II alleles, providing the widest population coverage and its superior immunological and anti-tumor properties in animal models. A link to the article can be found on Pubmed (PMID 21570434).

About Vaxil
Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

His lecture titled " ImMucin: the future of cancer vaccines " will present the novelty of Vaxil’s cancer vaccine technology, VaxHit and developments with ImMucin, Vaxil’s anti MUC1 cancer vaccine which is currently being evaluated in a Phase I/II clinical trial in Myeloma patients. The lecture will take place on May 24^th at 11:30 in Hall B.

About Vaxil
Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

His lecture titled "Signal Peptide Domains are broadly Immunogenic and have High CD8+ and CD4+ T-cell Epitope Densities: Implications for Vaccine Development" will present the novelty of Vaxil VaxHit platform technology for the isolation of better vaccine candidate and its applicability for lethal pathogens such as Mycobacterium tuberculosis. The lecture will take place on May 5^th at the Brain Research Centre of Bar Ilan University, Ramat Gan Israel.

 

“The fact that the VaxHit technology was selected to be presented at this prestigious international event in the company of such leading research groups from all over the world is a great honour to the company and tribute to our approach” said Dr. Lior Carmon, Vaxil’s Founder and CEO.

About Vaxil
Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

The lecture, titled developing a new Tuberculosis vaccine: Challenges and current status will examine the threat posed by Tuberculosis both to the developing and the developed world. It will examine current efforts to develop a new potent vaccine in place of the current ineffective BCG vaccine and will also present MTBuVax, Vaxil’s prophylactic and therapeutic vaccine for the disease. The lecture will take place on April 27^th at the Dan Tel-Aviv Hotel, Tel-Aviv Israel.

About Vaxil
Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

The studies demonstrated that mice vaccinated with MTbuVax produced potent CD4+ and CD8+ T-cell immunity that specifically proliferated in response to the MTbuVax vaccine. In addition, T-cells from vaccinated mice effectively eliminated target cells infected with the live MTb bacteria. This potent immune response was achieved following a regimen of only two vaccinations with MTbuVax without the use of any adjuvant, supporting the novelty of VaxHit-derived peptide vaccines.

These experiments were the first stage in a two stage program to evaluate MTbuVax in animal studies. MTbuVax is now being tested in protection studies in a secure facility at the University of Medicine and Dentistry New Jersey (UMDNJ) under the direction of Professor Gila Kaplan.
Dr. Lior Carmon, Founder and CEO of Vaxil commented “This is a very promising result which confirms what we have already seen in an earlier study which we carried out in conjunction with the Maccabi HMO when we tested MTbuVax on blood samples from over 20 patients who are sick with TB”.

About Vaxil
Vaxil is a private clinical stage biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients at Hadassah Medical Center, Jerusalem. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

The article entitled “Signal Peptide and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: implications for vaccines development” describes the robust antigen specific immunogenicity and wide population coverage of Signal Peptide domains as opposed to non-Signal Peptide sequences derived from the same proteins. A link to the article can be found on vaxilbio.com or on Pubmed (PMID 21316766).

“This is a very important validation by the scientific community of Vaxil’s unique approach to vaccine development and the advantages it offers”, comments Lior Carmon, Founder and CEO of Vaxil. “Of course it is crucial to receive clinical validation of our approach and we anticipate getting these answers from the current Phase I/II clinical trial in Myeloma patients using ImMucin, the first VaxHit derived vaccine to enter human studies”.

About Vaxil

Vaxil is a private biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.

For more information on the conference please visit
http://www.visiongain.com/Conference/271/Vaccine-Research-Innovation-2011

About Vaxil BioTherapeutics
Vaxil is a private biopharmaceutical company developing a new class of synthetic T-cell vaccines based on its proprietary VaxHit technology. Vaxil’s lead product ImMucin is an anti-MUC1 therapeutic vaccine and is currently being evaluated in a Phase I/II clinical trial in Multiple Myeloma patients. ImMucin is potentially applicable to over 90% of all types of cancer, encompassing both solid and non-solid tumors. Vaxil is also developing another VaxHit derived vaccine, MTbuVax, for the treatment of Mycobacterium Tuberculosis (MTb) which is in pre-clinical studies. Tuberculosis is one of the biggest causes of mortality worldwide. Recent years have seen a significant rise in the prevalence of treatment resistant TB, particularly in the developed world.